Results for: GLP-1RA

AstraZeneca, through its exclusive licensing agreement with Eccogene, is advancing the development of ECC5004, a potential oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for obesity treatment. Early data from clinical trials presented at ObesityWeek 2024 suggests ECC5004 exhibits a favorable safety profile, has the potential for once-daily dosing, and may be administered with or without food. This promising early data positions AstraZeneca to be a potential contender in the competitive weight loss market.

A new study suggests that semaglutide, a popular diabetes medication, could be linked to a lower risk of opioid overdose in patients with type 2 diabetes and opioid use disorder. This finding could open doors for a new use of this blockbuster drug, but more research is needed to confirm its efficacy and investigate the underlying mechanisms.